For the Inventor, By the Inventor

Enter inventor name

San Diego, CA, United States of America

Gian Luca Araldi

USPTO Granted Patents = 28 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 206(Granted Patents)

Location History:

Washington, DC (US) (2001 - 2004)
Quincy, MA (US) (2004)
Smithtown, NY (US) (2007)
Sedauket, NY (US) (2008 - 2010)
San Diego, CA (US) (2002 - 2011)
Plymouth, MA (US) (2007 - 2011)

Company Filing History:

Georgetown University

Laboratoires Serono S.a.

Corvas International, Inc.

4. 3 out of 145

Merck Serono S. A.

5. 2 out of 156

Applied Research Systems Ars Holding N.v.

Biostream Therapeutics, Inc.

Dendreon San Diego LLC

Dendreon Corporation

9. 2 out of 832,843

Other

patents

Years Active: 2001-2011

Loading Chart...

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8058305 - Pyrrolidine derivatives as prostaglandin modulators (2011-11-15),

2. 8044103 - Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders (2011-10-25),

3. 7863312 - Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors (2011-01-04),

4. 7696243 - [object Object] (2010-04-13),

5. 7635713 - Pyrrolidine derivatives as prostaglandin modulators (2009-12-22),

6. 7465755 - Hydrazide derivatives as prostaglandin receptors modulators (2008-12-16),

7. 7419999 - Gamma lactams as prostaglandin agonists and use thereof (2008-09-02),

8. 7410991 - Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors (2008-08-12),

9. 7335680 - Pyrrolidine derivatives as prostaglandin modulators (2008-02-26),

10. 7276531 - G-lactam derivatives as prostaglandin agonists (2007-10-02),

11. 7202279 - Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders (2007-04-10),

12. 7157596 - Inhibitors of serine protease activity of matriptase or MTSP1 (2007-01-02),

13. 6825211 - Bicyclic metabotropic glutamate receptor ligands (2004-11-30),

14. 6806281 - Analogs of cocaine (2004-10-19),

15. 6797504 - Inhibitors of serine protease activity of matriptase or MTSP1 (2004-09-28),

Title: The Innovations of Gian Luca Araldi: Enhancing Healthcare and Neuroprotection

Introduction: Gian Luca Araldi, a prolific inventor based in San Diego, CA, has made significant contributions to the fields of healthcare and neuroprotection through his groundbreaking inventions and patents.

Latest Patents: Gian Luca Araldi's latest patents include the development of pyrrolidine derivatives as prostaglandin modulators. These compounds offer a novel approach to treating a range of health conditions such as preterm labor, asthma, infertility, and bone disorders. Additionally, his work on cyclic dipeptides and azetidinone compounds demonstrates a promising avenue for enhancing memory and treating neurological disorders, especially those caused by CNS trauma.

Career Highlights: With an impressive portfolio of 28 patents, Gian Luca Araldi has established himself as a leading innovator in the medical field. His pioneering research has not only improved existing treatments but also opened up new possibilities for addressing challenging medical conditions.

Collaborations: Throughout his career, Gian Luca Araldi has collaborated with esteemed colleagues such as Alan P Kozikowski and Zhong Zhao. His partnerships with notable researchers and institutions, including Georgetown University and Laboratoires Serono S.a., have played a pivotal role in advancing his work and bringing innovative solutions to the forefront.

Conclusion: In conclusion, Gian Luca Araldi's inventive spirit and dedication to improving healthcare and neuroprotection have undoubtedly left a lasting impact on the field of medicine. His patents reflect a commitment to innovation and a relentless pursuit of solutions that have the potential to transform the lives of many.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…